Liver cancer patients get targeted chemo after surgery to stop return
NCT ID NCT07337421
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether giving a specific chemotherapy cocktail (mFOLFOX) directly into the liver artery after surgery can prevent liver cancer from coming back in patients at high risk. About 30 adults who had their liver cancer removed will receive up to two rounds of this infusion. Researchers will track how long patients stay cancer-free and monitor side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
mFOLFOX (oxaliplatin, leucovorin calcium, and 5-fluorouracil) given directly into the liver artery
What this could lead to
If it works, this could offer a way to lower the chance of liver cancer coming back after surgery for patients at high risk.
What could go wrong
This is a small, early-phase trial with only 30 participants and no comparison group, so results may not apply widely. The chemotherapy can cause side effects like nerve damage, low blood counts, and digestive issues.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA (HCC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Clinical Medical College of Yangzhou University
RECRUITINGYangzhou, Jiangsu, 225001, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••